Posted on 22/07/03
Biovail says research and others say conflict
Should doctors be paid to prescribe certain drugs? Most patients and specialists in medical ethics would probably argue they should not, because doing so might pose a conflict of interest, and cause them to prescribe drugs that might not be as effective. But what if the doctor in question is involved in a research trial? Shouldn't he or she be compensated for collecting data on the drug? Canadian drug giant Biovail, which seems to have a knack for attracting controversy, has landed smack in the middle of the grey area between those two questions with its drug Cardizem.
The full text of this article has 897 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
